Fairway was founded in 1992 to commercialize a sophisticated FDA Class III ( life support ) blood pump and console technology and became a portfolio company of BCM Technologies, the technology transfer entity of Baylor College of Medicine. In 2000, Fairway acquired the medical device design, engineering and manufacturing division of KVM Technologies, Inc The KVM acquisition transformed the company into a vertically integrated technology company with a strong bioengineering management team. This acquisition also permitted Fairway to leverage KVM's quality plan and previous 20 year history of FDA audits with no cited deficiencies. In 2009, Fairway Medical Technologies and In3 Ventures ( Invention-Innovation-Investment Ventures, an early-stage Houston-based medical technology incubator company founded in 2007 by Dr. Morteza Naghavi ) merged operations after a major equity transfer. This merger significantly increased Fairway's medical expertise, particularly in the area of cardiovascular medicine and technologies. Over the years, Fairway's management has commercialized over 30 medical devices and has created significant intellectual property ( over 50 patents ) in the process. Working closely with leading physicians and scientists of world-class TMC institutions, such as MD Anderson Cancer Center, University of Texas Health Science Center, and Baylor College of Medicine, has given Fairway years of hands-on preclinical and clinical experience, a major competitive advantage rarely found in other firms. Fairway's management and advisory team is enriched with an unmatched combination of elite physician scientists, biomedical engineers, university faculty, and prominent local business and financial experts. Fairway has also earned a number of technology commercialization grants from the National Institute of Health as well as the State of Texas' Emerging Technology Fund ( ETF ). Currently, Fairway is the only Texas based medical technology company with over $10 Million in NIH grants and $6 Million in ETF grants awarded to 4 Fairway Portfolio Companies. In addition to supporting early stage startups with technology development and seed capital, Fairway helps them obtain SBIR ( Small Business Innovative Research ) and other grants. OUR BUSINESS MODEL Fairway's business plan is focused on facilitating the commercialization of promising, early stage medical devices and technologies. We execute our business plan utilizing our skilled team of inventors, physicians, medical device experts, and bioengineers through the following processes: Stringent screening and due diligence, which includes clinical, engineering, intellectual property, FDA regulatory, business and financial analyses. Technology enrichment, which usually includes additional IP development, design innovation, and advanced engineering, in addition to initial modeling and prototype design. Enabling regulatory approval, by strategic planning, establishing the infrastructure and critical path to minimize delay and reduce costs.